Get the Stockscreener App
65.54
2.33%
-1.6173
Soleno Therapeutics Inc stock is traded at $65.54, with a volume of 1.45M.
It is down -2.33% in the last 24 hours and up +10.78% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$67.16
Open:
$68
24h Volume:
1.45M
Relative Volume:
0.81
Market Cap:
$3.48B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-21.87
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-2.84%
1M Performance:
+10.78%
6M Performance:
-12.81%
1Y Performance:
+17.43%
1-Day Range:
$64.90
$69.99
1-Week Range:
$64.90
$72.80
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
65.55 | 3.57B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Published on: 2025-11-03 08:08:49 - newser.com
Is Soleno Therapeutics Inc. (6XC) stock good for long term investingLong Setup & Entry Point Confirmation Signals - newser.com
Can Soleno Therapeutics Inc. stock outperform in 2025 bull market2025 Earnings Surprises & Safe Entry Momentum Tips - newser.com
Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Report Preview: What To Look For - GuruFocus
Will Soleno Therapeutics Inc. stock reach Wall Street targetsTrade Risk Assessment & Consistent Income Trade Recommendations - newser.com
Full technical analysis of Soleno Therapeutics Inc. stockWeekly Trade Summary & AI Optimized Trading Strategy Guides - newser.com
How moving averages guide Soleno Therapeutics Inc. tradingAnalyst Downgrade & Long-Term Safe Investment Plans - newser.com
Will Soleno Therapeutics Inc. (6XC) stock outperform small cap peersPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Order flow analysis tools used on Soleno Therapeutics Inc.Quarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
What hedge fund activity signals for Soleno Therapeutics Inc. stock2025 Trade Ideas & Real-Time Volume Analysis Alerts - newser.com
Moody Aldrich Partners LLC Has $3.48 Million Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
How Soleno Therapeutics Inc. stock benefits from strong dollarJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
Soleno Therapeutics, Inc. $SLNO Shares Acquired by Emerald Mutual Fund Advisers Trust - MarketBeat
Is Soleno Therapeutics Inc. a candidate for recovery play2025 Market Sentiment & Consistent Growth Equity Picks - newser.com
Has Soleno Therapeutics Inc. formed a bullish divergenceBull Run & Risk Controlled Stock Pick Alerts - newser.com
Is Soleno Therapeutics Inc. stock a bargain at current levelsEarnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
Will Soleno Therapeutics Inc. outperform the marketWeekly Trade Recap & Reliable Breakout Stock Forecasts - newser.com
Will Soleno Therapeutics Inc. stock benefit from upcoming earnings reportsMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Soleno Therapeutics (SLNO): Assessing Valuation Following Securities Probe and Short-Seller Safety Allegations - Sahm
Strategies to average down on Soleno Therapeutics Inc.July 2025 Closing Moves & Consistent Income Trade Ideas - newser.com
Will Soleno Therapeutics Inc. stock outperform tech sector in 2025Portfolio Return Report & Safe Entry Zone Identification - newser.com
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO - Bluefield Daily Telegraph
Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Soleno Therapeutics, Inc. $SLNO is Emerald Advisers LLC's 6th Largest Position - MarketBeat
Soleno Therapeutics Stock Jumped 5.2% in a Day, What Now? - Trefis
What analysts say about Soleno Therapeutics Inc stockGap Up/Gap Down Analysis & Never Miss the Next Wealth Opportunity - earlytimes.in
Soleno Therapeutics to Participate in Upcoming November Conferences - The Manila Times
Soleno Therapeutics (NASDAQ: SLNO) sets November talks at Guggenheim and Jefferies - Stock Titan
Published on: 2025-10-27 22:15:31 - newser.com
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):